Cadus Corp.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cadus Corp.
Teva Breaks Out OTC Sales Figures In Bid To Play Up Diversification
Teva Pharmaceutical Industries reported OTC product sales for the first time Feb. 15. The Jerusalem firm said OTC net revenue was $765 million in 2011, up 54.2% and attributable largely to the acquisition of German firm ratiopharm and the PGT Healthcare joint venture with Procter & Gamble.
Teva Breaks Out OTC Sales Figures In Bid To Play Up Diversification
Teva Pharmaceutical Industries reported OTC product sales for the first time Feb. 15. The Jerusalem firm said OTC net revenue was $765 million in 2011, up 54.2% and attributable largely to the acquisition of German firm ratiopharm and the PGT Healthcare joint venture with Procter & Gamble.
People In Brief
Bristol-Myers exec to head Teva; GSK’s Witty now Sir Andrew; ISPE names Berg president; more People In Brief.
Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers
Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice